Overview

Study of LY3039478 in Healthy Participants

Status:
Completed
Trial end date:
2016-11-11
Target enrollment:
Participant gender:
Summary
The study involves one dose of LY3039478 given by mouth followed by an intravenous infusion (IV) (via a tube linked to a small needle in the vein) of LY3039478. The results of this study will help to answer the following research questions: - How much LY3039478 gets into the blood stream when given by mouth as a capsule compared to when given by an IV - How long it takes the body to remove the study drug - The safety of LY3039478 and any side effects that might be associated with it Participation in the study is expected to last up to 7 weeks. There will be screening, a single study period, and a follow-up.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company